SWP
LGND icon

Strategic Wealth Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Strategic Wealth Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-160
Closed -$9 – 339
2019
Q3 		$9 Hold
160
– – ﹤0.01% 585
2019
Q2 		$11K Hold
160
– – 0.01% 477
2019
Q1 		$12K Hold
160
– – 0.01% 465
2018
Q4 		$13K Buy
+160
New +$17.1K 0.01% 417

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Strategic Wealth Partners's LGND Position: Q4 2019 in Review

Strategic Wealth Partners sold out of Ligand Pharmaceuticals (LGND) in Q4 2019, closing a stake of 160 shares — an estimated $9 sold.

Strategic Wealth Partners first reported a position in LGND in Q4 2018 and held it in 4 quarters. The position peaked at $13K in Q4 2018. 266 funds tracked by Wall St. Rank hold LGND as of Q4 2019.

  • Strategic Wealth Partners reported no remaining Ligand Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Strategic Wealth Partners sold 160 Ligand Pharmaceuticals shares in Q4 2019, an estimated $9.
  • Strategic Wealth Partners first reported a position in Ligand Pharmaceuticals in Q4 2018 and held it in 4 quarters.
  • Strategic Wealth Partners's Ligand Pharmaceuticals position peaked at $13K in Q4 2018.
  • 266 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2019.

Based on Strategic Wealth Partners's 13F filing for Q4 2019, filed 30 Jan 2020.